DM Gastroenterology AIIMS, Delhi, Advanced fellowship in IBD
University of Western Ontario Canada
and
Nottingham University Hospitals NHS trust, United Kingdom
After a incredible journey of learning, IBD fellowship came to an end. My heart felt thanks to my extraordinary mentor
@vipuljairath
and wonderful team. Excited for the next chapter in my life
@WesternU
@SchulichMedDent
Do we need to wait for washout of biologics when switching?
Limited evidence.
Our study fills the gap!
We found that early switch is safe!
@vipuljairath
@WesternU
Checkout our new paper on stoma.
Majority focussed on devices and surgical procedures
Limited studies in CD and none evaluating medical therapies.
There is urgent need for future research in CD with stoma.
@IBD_FloMD
@vipuljairath
@NarulaNeeraj
Our recent publication on scoring indices for pCD.
Although there are many indices, none of them are fully validated. Much more work is required in this area.
@vipuljairath
@virgisolitano
#JCC
@theliverdr
This is a carefully planned proof of concept study backed by sound scientific evidence and biological plausible rationale from a premier institute which is leading high quality IBD research in India.
@theliverdr
An in vitro study from AIIMS showed effect of potassium significantly reduced the IL-17 and IFNγ expression on Th17 cells and also promoted the Foxp3 expression in a dose dependent manner. Several other studies support the same.
DOI: 10.1038/s41598-017-18046-x
@shanilkadir
@IBD_Afzali
@ibdseb
@ibdnurse
@DCharabaty
A course of antibiotics+ loose Seton + increase dose of IFX. If no response drug levels and ABs
Can try changing to ADA
If no response other therapies Which can be tried depending on availability
VAAFT
HBOT
Mesenchymal stem cell injection
@theliverdr
It is well reported that potassium has immune modulatory properties. Many studies have shown that over expression of potassium channels in inflammatory cells in active UC.
DOI: 10.1016/j.crohns.2014.04.003
doi: 10.1016/j.yexmp.2016.03.009
DOI: 10.3389/fimmu.2016.00554
Interesting study
New therapeutic target in IBD
Bezedoxifene(gp130 blocker) reduces DSS mediated bowel injury in NOD2 mutated zebrafish
A myeloid–stromal niche and gp130 rescue in NOD2-driven Crohn’s disease
@theliverdr
This study was conducted to see if potassium rich diet/coconut water in this case aids in reducing inflammation in mild to moderate active UC along with standard medical therapy but not as standalone therapy.
@drvishal82
@drdeepakmadhu
@morerajdeep
@Sanchit30497977
Differentiating ITB from CD is still an enigma. None of the present scoring system or investigations are 100% specific and sensitive. For a given patient its either TB or CD. Combination of clinical, radio, histopath and other inv aid in diagnosis. Mx should be individualised.
Another indication for FCP
Validation of the Red Flags Index for Early Diagnosis of Crohn’s Disease: A Prospective Observational IG-IBD Study Among General Practitioners
@morerajdeep
@drvishal82
@drdeepakmadhu
@Sanchit30497977
Ulcers look non specific. Difficult to say TB or CD. In our center we do CT chest (pulm TB) and FOXP3 levels also. If still inconclusive we can try ATT trial and repeat colonoscopy after 2months.
@propelacure
@IBD_FloMD
Wonderful work
@IBD_FloMD
Any thoughts on mechanisms of colonic structures and why creeping fat is not so common in the colon...
@bottomlineibd
Kuwahara E et al. J Gastroenterol 2012; 47: 961–968.
Banerjee R, et al. Intest Res 2019; 17: 486–495.
Palli D, et al. The Euro J of Public Health 1997; 7: 109–112.
Moller FT, et al. Am J Gastroenterol 2015; 110: 564–571.
Childers RE, et al. J Crohns Colitis 2014; 8: 1480–1497.